T cells redirected to interleukin-13Rα2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1-Reference-Cited by-同舟云学术

T cells redirected to interleukin-13Rα2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1

Published:2014-08 Issue:8 Volume:16 Page:1121-1131
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Krebs Simone,Chow Kevin K.H.,Yi Zhongzhen,Rodriguez-Cruz Tania,Hegde Meenakshi,Gerken Claudia,Ahmed Nabil,Gottschalk Stephen

Funder

The Dana Foundation

The Clayton Foundation for Research

James S. McDonnell Foundation

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference37 articles.

1. Immunotherapeutic approaches for glioma;Okada;Crit Rev Immunol,2009

2. Toward effective immunotherapy for the treatment of malignant brain tumors;Mitchell;Neurotherapeutics,2009

3. Cellular immunotherapy for high-grade glioma;Chow;Immunotherapy,2011

4. Immunotherapy for glioma: getting closer to the clinical arena?;Finocchiaro;Curr Opin Neurol,2011

5. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions;Curran;J Gene Med,2012

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and characterisation of novel CAR‐T cells to target IL13Rα2 positive human glioma in vitro and in vivo;Clinical and Translational Medicine;2024-04-29

2. CAR-T Cell Therapy: From the Shop to Cancer Therapy;International Journal of Molecular Sciences;2023-10-28

3. Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics;Environmental Research;2023-10

4. Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy;International Journal of Molecular Sciences;2023-09-28

5. Engineering the IL‐4/IL‐13 axis for targeted immune modulation;Immunological Reviews;2023-06-07